Ark Biosciences' Anti-RSV AK0529 Successfully Completes Phase I Study
Ark Biosciences announced the successful completion of phase 1 clinical study of its anti-respiratory syncytial virus (RSV) drug AK0529...
know more >
Ark Biosciences Completes Series A Financing and Reports Significant Progress for AK0529
Ark Biosciences announced successful completion of a Series A financing...
know more >
Ark Biosciences Licenses Novel Drug Candidate from Roche for Potential Treatment of RSV infection
Ark Biosciences announced a licensing agreement for Roche's Respiratory Syncytial Virus (RSV) drug candidate AK0529...
know more >